Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kashinkunti, MD
- Fascioscapulohumeral Muscular Dystrophy- A Case Report
Abstract Views :243 |
PDF Views:0
Authors
Affiliations
1 Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, IN
1 Department of Medicine, SDM College of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, IN
Source
International Journal of Contemporary Medicine, Vol 1, No 2 (2013), Pagination: 15-17Abstract
Fascioscapulohumeral dystrophy (FSHD) is the third most common form of muscular dystrophy. It should be considered in patients with complaints of progressive weakness. We present the case of a man with facial, arms and leg weakness. Clinically diagnosed as FSHD. Electro diagnostic testing revealed findings consistent with a myopathic disorder. Subsequent genetic testing identified a FSHD allele size consistent with a FSHD deletion mutation, thus confirming the diagnosis of FSHD. Unfortunately, no effective treatments currently exist for FSHD. However, supportive measures involving physical therapy and the use of orthotics may aid in improving function and mobility.Keywords
Fascioscapulohumeral, Muscular Dystrophy, Electro Diagnostic Testing.
References
- Landoyzy L, Dejerine J. Contribution à l’étude de la myopathie atrophique progressive (myopathie atrophique progressive, à type scapulo-huméral). Comptes rendus de la Société debiologie 1886; 38:478–81.
- Kilmer DD, Abresch RT, McCrory MA, Carter GT, Fowler WM Jr, Johnson ER et al. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 1995;74:131–39.
- Chung CS, Morton NE. Discrimination of genetic entities in muscular dystrophy. Am J Hum Genet 1959;11:339–59.
- Padberg GW, Lunt PW, Koch M, Fardeau M. Facioscapulohumeral muscular dystrophy. In: Emery AEH, ed. Diagnostic criteria for neuromuscular disorders. The Netherlands: European Neuromuscular Center,1997:9–15.
- Hewitt JE, Lyle R, Clark LN, Valleley EM, Wright TJ, Wijmenga C et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet. 1994;3:1287–1295.
- N S T Thomas, K Wiseman, G Spurlock, M MacDonald, D Üstek, and M Upadhyaya. A large patient study confirming that facioscapulohumeral muscular dystrophy (FSHD) disease expression is almost exclusively associated with an FSHD locus located on a 4qA defined 4qter subtelomere. J Med Genet. 2007 March; 44(3): 215–218.
- Podnar S, Zidar J. Sensitivity of motor unit potential analysis in facioscapulohumeral muscular dystrophy. Muscle Nerve 2006;34: 451–456.
- Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC, Tawil R. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology. 2001; 57:1434–40.
- Cutaneous Leishmaniasis: Case Report from Tertiary Care Hospital from North Karnataka
Abstract Views :224 |
PDF Views:0
Authors
MD Kashinkunti
1,
M
1
Affiliations
1 Department of Medicine, SDM college of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, IN
1 Department of Medicine, SDM college of Medical Sciences and Hospital, Sattur, Dharwad, Karnataka, IN
Source
International Journal of Contemporary Medicine, Vol 1, No 2 (2013), Pagination: 62-64Abstract
Cutaneous leishmaniasis is the most common form of leishmaniasis caused by flagellate protozoa of the genus Leishmania transmitted by sand fly bites. Old World leishmaniasis is endemic in the Mediterranean Sea and the neighboring countries. We present a case of a 19 year old girl with a cutaneous leishmaniasis in form of papules on the nose. Histopathological examination showed diffuse dermal infiltrate predominantly of macrophages with admixture of few lymphocytes, eosinophils and plasma cells. In most of macrophages amastigotes were seen. Because of higher rate of travel and work abroad increased number of sporadic cases of cutaneous leishmaniasis in non-endemic areas should be taken into account.Keywords
Cutaneous Leishmaniasis, Sand Fly, Amastigotes.References
- WHO. The world health report 2004. Changing history. Geneva: WHO, 2004. http:// www.who.int/whr/2004/en/index.html
- WHO. Cutaneaous Leishmaniasis: An overview: Symposium. J Postgrad Med 2003;49:50.
- Sehgal S, Mittal V, Bhatia R. Manual on laboratory techniques in Leishmaniasis. 2nd ed. NICD: Delhi; 1989. p. 2-4.
- Hengge UR, Marini A. Cutaneous leishmaniasis. Hautarzt2008;59:627–32.
- Bryceson ADM. Immunological aspects of cutaneous leishmaniasis. Essays on Tropical Dermatology 1972: 230.
- Sidney N. Klaus, Shoshana Frankenburg, A. Damian Dhar, et al. Leishmaniasis and other Protozoan Infection. In: IM Freedberg AZ Eisen, Klaus Wolff,et al., eds. Fitzpatrick’s Dermatology in General Medicine. 6th ed. McGraw Hills 2003;2(6):2215-20.
- Sengupta PC, Bhattacharjee B. Histopathology of post kala-azar dermal leishmaniasis. J Trop Med Hyg 1953;56:110-6.
- Schwarz KJ. Diagnosis and differential diagnosis of cutaneous leishmaniasis. Report on seven cases observedin Zurich. Schweiz Med Wochenschr1970;100:2073–8.
- Eileen D. Franke, Alejandro Llanos-Cuentas, Juan Echevarria, Maria E. Cruz,Pablo Campos, Adolfo A et al. Efficacy of 28-Day and 40-Day Regimens of Sodium Stibogluconate (Pentostam) in the Treatment of Mucosal Leishmaniasis. Am J Trop Med Hyg July 1994 51:77-82.